Cytori Patents Method of Treating Renal Diseases Using Adipose-Derived Regenerative Cells

  Cytori Patents Method of Treating Renal Diseases Using Adipose-Derived
  Regenerative Cells

Business Wire

SAN DIEGO -- March 28, 2013

Cytori Therapeutics (NASDAQ: CYTX) received US Patent No. 8,404,229 (the ‘229
patent) for methods of treating renal diseases using adipose-derived
regenerative cells (ADRCs). The ‘229 patent covers treatment of a broad range
of renal disorders, including acute kidney disease (AKD) and chronic kidney
disease (CKD). The ‘229 patent also covers multiple means of delivering the
ADRCs, including to the kidney directly, to the renal vasculature or to the
renal parenchyma.

The ‘229 patent complements Cytori’s previously issued European Patent No. 1
778 834 (the ‘834 patent) directed to the treatment of renal disorders.
Similar to the ‘229 US patent, the ‘834 European patent covers treatment of a
broad range of renal disorders, including AKD and CKD. The ‘834 patent is
effective in the United Kingdom, Germany, France, Netherlands, Spain, Belgium,
Sweden, and select other European countries. Cytori now has 60 issued patents
and more than 75 active patent applications worldwide.

“The renal patents are an important addition to our growing portfolio of ADRC
patents,” said Chris Calhoun, Chief Executive Officer of Cytori. “CKD is an
important co-morbidity of cardiovascular disease, Cytori’s core focus. Our
platform technology and recent European approval of Intravase® for
intravascular delivery allows us to explore related indications without
compromising our focus on the core indications. Potentially, we would partner
this indication to expedite bringing this therapy to market.”

Cytori’s renal patents reflect the Company’s previously published preclinical
data showing that ADRCs improve renal function and reduce mortality in acute
kidney injury (AKI). AKI represents a major clinical problem with high
mortality and limited causal treatments. In the study, animals received either
ADRCs or control after a renal injury was induced. Specific markers for kidney
function and survival were assessed daily for seven days. Survival in the ADRC
treated group was 100% and a statistically significant outcome compared to
only 57% survival in the control group (p<0.005). Statistically significant
functional and histologic improvements were also shown in serum creatinine
(p<0.0001), blood urea nitrogen (p<0.0001) and renal cell necrosis (p<0.0001).
This study provides substantial evidence of the potential of ADRC therapy for
treating acute kidney injury.

Renal Diseases

The Center for Disease Control estimates that more than 10% of Americans, or
20 million people, suffer from chronic kidney disease (CKD). In addition,
rates of acute kidney disease (AKD) are on the rise in the United States.
According to a University of California, San Francisco study published in
December 2012, on average, the incidence of AKD increased by 10% per year for
the past decade. In 2010, the US renal market was estimated to be worth $21.7
billion, based a 2011 report from GBI Research.

About Adipose Tissue and ADRCs

Adipose tissue is the richest source of stem and regenerative cells in the
body. This mixed population of cells, collectively referred to as ADRCs, is
accessible at the point-of-care through the Celution® System for use in the
same patient, creating new treatment opportunities for currently unmet medical
needs. ADRCs collectively contribute to the healing process via cell-to-cell
signaling, supporting improved blood flow and regulation of the inflammatory

About Cytori

Cytori Therapeutics is developing cell therapies based on autologous
adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and
other medical conditions. Our scientific data suggest ADRCs improve blood
flow, moderate the inflammatory response and keep tissue at risk of dying
alive. As a result, we believe these cells can be applied across multiple
"ischemic" conditions. These therapies are made available to the physician and
patient at the point-of-care by Cytori's proprietary technologies and
products, including the Celution® System product family.

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements regarding events,
trends and business prospects, which may affect our future operating results
and financial position. Such statements, including, but not limited to, those
regarding the possibility of gaining a partner to expedite bringing a renal
therapy to market, are subject to risks and uncertainties that could cause our
actual results and financial position to differ materially. Some of these
risks and uncertainties include the challenges inherent in convincing
physicians and patients to adopt the new technology, as well as our history of
operating losses, regulatory uncertainties, dependence on third party
performance, and other risks and uncertainties described under the "Risk
Factors" section in Cytori's Securities and Exchange Commission Filings on
Form 10-K and Form 10-Q. Cytori assumes no responsibility to update or revise
any forward-looking statements contained in this press release to reflect
events, trends or circumstances after the date of this press release.


Cytori Therapeutics Inc.
Megan McCormick, +1-858-875-5279
Tom Baker, +1-858-875-5258
Press spacebar to pause and continue. Press esc to stop.